COMPUGROUP MEDICAL - NEUTRAL | EUR78 VS. EUR84 (+29%) 2022 guidance offers no surprise – more proof of growth acceleration needed to be positiv
COMPUGROUP MEDICAL - NEUTRAL | EUR78 VS. EUR84 (+29%)2022 guidance offers no surprise – more proof of growth acceleration needed to be positive
2022 organic growth and EBITDA margin ranges too wide for our liking
2021 results delayed to early March due to a contained cyberattack
Impact from delay in e-prescription roll-out isn’t big for CGM
Reiterate neutral rating – lack of catalysts to be positive on the stock
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.